Bioprocess chemometrics market forecast to reach $3.27 billion by 2030

By AI, Created 5:26 PM UTC, May 18, 2026, /AGP/ – The Business Research Company says the bioprocess chemometrics market is on track to grow from $1.89 billion in 2025 to $3.28 billion by 2030 as biopharma firms lean more on data analytics, automation and AI. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Bioprocess chemometrics is becoming more important as biopharmaceutical production gets more complex and more regulated. - The market is projected to nearly double by 2030, signaling stronger demand for software and analytics that can improve process control, product quality and manufacturing efficiency. - The shift matters beyond pharma, with the forecast also pointing to broader use in food and environmental monitoring.

What happened: - The Business Research Company released a market outlook for bioprocess chemometrics on May 14, 2026. - The report estimates the market will rise from $1.89 billion in 2025 to $2.11 billion in 2026. - The forecast calls for the market to reach $3.28 billion by 2030, not $3.27 billion as framed in the headline, at an 11.7% CAGR. - North America was the largest regional market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Bioprocess chemometrics uses multivariate statistics and data-driven modeling to interpret complex data from biotechnology processes. - The approach analyzes sensor outputs, spectroscopic data and process parameters. - The goal is to improve monitoring, control and optimization of biomanufacturing systems. - Historical growth was driven by rising biopharmaceutical manufacturing, greater use of analytical instruments, deeper process understanding, spectroscopy and chromatography advances, and tighter regulatory compliance needs. - Future growth is expected to come from AI-driven bioprocess analytics, cloud-based data platforms, more automation, wider use in food and environmental monitoring, and tighter integration with bioreactor sensors and instrumentation. - Expected trends include real-time monitoring, more advanced process modeling software, multivariate data analysis integration, expanded consulting and implementation services, and more emphasis on optimizing biomanufacturing processes. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report offers a free sample and a full report.

Between the lines: - The market story is being shaped by two larger shifts: biopharma’s move toward more data-intensive manufacturing and the push for personalized medicine. - Sales growth in biologic drugs helps explain why producers need better analytics to keep output consistent across scales. - The report cites Sartorius AG data showing global sales of biopharmaceutical drugs reached $458 billion in 2024, equal to 41% of the total pharmaceutical market, up from 40% in 2023. - The report also points to personalized medicine as a driver, since patient-specific therapies require more precise manufacturing controls. - The Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Those approvals included seven cancer drugs and three treatments for other conditions.

What’s next: - Market growth is likely to track continued adoption of AI, cloud software and automation in bioprocessing. - Vendors and service providers are likely to see more demand for real-time monitoring tools, implementation support and modeling software. - Asia-Pacific’s faster growth suggests new sales opportunities as biomanufacturing capacity expands outside North America.

The bottom line: - Bioprocess chemometrics is moving from a niche analytics tool to a core layer of biomanufacturing as the industry scales more advanced biologics and personalized therapies.